

PPC Meeting, 31 October-1 November 2022

Discussion, Information and Guidance Items

- CEO Report
- COVAX – Key Strategic Issues

PPC Meeting, 31 October-1 November 2022

Recommendations to the Board

- Human papillomavirus (HPV) Vaccine Programme (*Agenda Item 7*)
- Gavi's role in support to Regional and African Vaccine Manufacturing (*Agenda Item 8*)
- Gavi's role in a future COVID-19 Vaccine Programme (*Agenda Item 10*)
- Funding Policy Review (*Agenda Item 11*)
- Gavi Support for Inactivated Poliovirus Vaccine (*Consent Agenda*)

PPC Meeting, 31 October-1 November 2022

CEO Update

- Acknowledged the Secretariat's work and continuous consultations with numerous stakeholders.
- The PPC underlined the importance of clear overview of available funding and suggested to receive a table to demonstrate the different funding envelopes.
- PPC members discussed the volume and length of papers as challenging for appropriate level feedback and engagement.
- Recognised the need to preserve pre-COVID-19 pandemic achievements and safeguard countries against future pandemic risks.
- Discussed potential additional PPC touchpoints.
- Highlighted the link between strategic discussions at the PPC and Partnerships Team (PT) level, noting PPC discussions feed back into PT discussions.

PPC Meeting, 31 October-1 November 2022

Strategy, Programmes and Partnerships: Progress, Risk and Challenges (*including update on Gavi 5.1 process*)

- In relation to the VIS 2018 vaccines, which had been paused during the COVID-19 pandemic, the PPC requested that next steps be discussed at its meeting in May 2023.
- PPC members commended the Risk & Assurance Report.
- The importance of continuing commitment to catching up missed children was emphasised.
- PPC members were encouraged by the number of Full Portfolio Planning (FPP) applications received.
- Discussed the four additional areas for Pandemic Preparedness and Respond (PPR) and encouraged continued momentum.

PPC Meeting, 31 October-1 November 2022

COVAX – Key Strategic Issues

- The PPC were supportive of extending the COVID-19 Vaccine Delivery Support Temporary Steering Committee until April 2023.
- PPC members encouraged the Secretariat to document the excellent work by COVAX and the overall COVID-19 vaccine delivery operations and which could translate across to routine immunisations.
- Country vaccine demand, and the impact of shifting focus of vaccine manufacturers from ancestral prototype to bivalent vaccine production, was discussed.
- Encouraged the Secretariat to bring learnings from the COVAX Humanitarian Buffer into overall preparedness planning.

PPC Meeting, 31 October-1 November 2022

Consent Agenda – Gavi Support for Inactivated Poliovirus (IPV) Vaccine

- PPC members supported the continuation of the IPV approach and commended the collective teamwork.
- PPC members underlined the importance of integration and leveraging the polio programme integration to reach zero-dose children.
- PPC members encouraged continued partner engagement.
- Encouraged the Secretariat to conduct broad consultations in planning towards country ownership of IPV in terms of cost-sharing and vaccine equity with IPV, hexavalent and other antigens.
- Highlighted the challenges for some countries in accessing the vaccine and expressed concern that some high-risk countries had not as yet applied for IPV2 support.

PPC Meeting, 31 October-1 November 2022

Recommendations to the Board

- Listed in Annex B
- Further details from the PPC discussions contained in the relevant papers to the Board, listed in slide 3

Thank you